AtriCure, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
February 15, 2024 at 04:01 pm EST
Share
AtriCure, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported sales was USD 106.54 million compared to USD 88.03 million a year ago. Revenue was USD 106.54 million compared to USD 88.03 million a year ago. Net loss was USD 9.79 million compared to USD 4.17 million a year ago. Basic loss per share from continuing operations was USD 0.21 compared to USD 0.09 a year ago. Diluted loss per share from continuing operations was USD 0.21 compared to USD 0.09 a year ago.
For the full year, sales was USD 399.25 million compared to USD 330.38 million a year ago. Revenue was USD 399.25 million compared to USD 330.38 million a year ago. Net loss was USD 30.44 million compared to USD 46.47 million a year ago. Basic loss per share from continuing operations was USD 0.66 compared to USD 1.02 a year ago.
AtriCure, Inc. provides technologies for the treatment for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management. The Company's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. The Company's products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System. The Isolator Synergy Ablation System clamps are single-use disposable radio frequency (RF) products with jaws that close in a parallel fashion.
ATRICURE, INC. 
